J Rheum Dis.  2019 Apr;26(2):93-103. 10.4078/jrd.2019.26.2.93.

Psychiatric Symptoms in Systemic Lupus Erythematosus: Diagnosis and Treatment

• Yoon S
• Kang DH
• Choi TY

• KMID: 2442019
• DOI: http://doi.org/10.4078/jrd.2019.26.2.93

Abstract

According to the American College of Rheumatology classification, lupus erythematosus has five psychiatric manifestations, including cognitive dysfunction, mood disorder, anxiety disorder, psychosis, and acute confusional state, which are frequently accompanied by other symptoms. Cognitive dysfunction is the most common psychiatric manifestation in lupus patients with a prevalence rate ranging from 20% to 80%. The expression of psychiatric manifestations has been considered to be associated with disease activity, side effects of medications, and/or psychosocial stresses from the chronicity of lupus, but this has not been fully understood. Appropriate management of psychiatric symptoms is essential as it affects treatment adherence and quality of life. This review aimed to facilitate understanding of psychiatric manifestations of lupus through literature review on the prevalence, clinical features, diagnosis, and treatments of each psychiatric symptom.

Keyword

Lupus erythematosus; systemic; Mental disorders; Diagnosis; Therapeutics

MeSH Terms

Anxiety Disorders
Classification
Diagnosis*
Humans
Lupus Erythematosus, Systemic*
Mental Disorders
Mood Disorders
Prevalence
Psychotic Disorders
Quality of Life
Rheumatology

Reference

1. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014; 10:579–596.

2. Ginzler EM, Dvorkina O. Newer therapeutic approaches for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005; 31:315–328.

3. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011; 41:1–11.

4. Calderón J, Flores P, Aguirre JM, Valdivia G, Padilla O, Barra I, et al. Impact of cognitive impairment, depression, disease activity, and disease damage on quality of life in women with systemic lupus erythematosus. Scand J Rheumatol. 2017; 46:273–280.

5. Shen B, Feng G, Tang W, Huang X, Yan H, He Y, et al. The quality of life in Chinese patients with systemic lupus erythematosus is associated with disease activity and psychiatric disorders: a path analysis. Clin Exp Rheumatol. 2014; 32:101–107.

6. Shen B, Tan W, Feng G, He Y, Liu J, Chen W, et al. The correlations of disease activity, socioeconomic status, quality of life, and depression/anxiety in Chinese patients with systemic lupus erythematosus. Clin Dev Immunol. 2013; 2013:270878.

7. Greco CM, Li T, Sattar A, Kao AH, Danchenko N, Edmundowicz D, et al. Association between depression and vascular disease in systemic lupus erythematosus. J Rheumatol. 2012; 39:262–268.

8. Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2017; 69:1706–1713.

9. Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599–608.

10. Hanly JG. Avoiding diagnostic pitfalls in neuropsychiatric lupus: the importance of attribution. Lupus. 2017; 26:497–503.

11. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford). 2002; 41:605–618.

12. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002; 58:1214–1220.

13. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983; 5:319–332.

14. Purandare KN, Wagle AC, Parker SR. Psychiatric morbidity in patients with systemic lupus erythematosus. QJM. 1999; 92:283–286.

15. van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, et al. Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus. 2013; 22:1462–1469.

16. Bortoluzzi A, Scirè CA, Bombardieri S, Caniatti L, Conti F, De Vita S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015; 54:891–898.

17. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007; 56:265–273.

18. Stojanovich L, Zandman-Goddard G, Pavlovich S, Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev. 2007; 6:421–426.

19. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016; 76:459–483.

20. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010; 69:2074–2082.

21. Kupfer DJ. The American Psychiatric Publishing textbook of psychiatry. 6th ed. Washington DC: American Psychiatric Publishing;2014.

22. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001; 57:496–500.

23. Gendelman O, Tiosano S, Shoenfeld Y, Comaneshter D, Amital H, Cohen AD, et al. High proportions of dementia among SLE patients: a big data analysis. Int J Geriatr Psychiatry. 2018; 33:531–536.

24. Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum. 2004; 51:810–818.

25. Waterloo K, Omdal R, Sjöholm H, Koldingsnes W, Jacobsen EA, Sundsfjord JA, et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol. 2001; 248:595–602.

26. Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol. 1994; 21:1825–1831.

27. Mak A, Ho RCM, Lau CS. Clinical implications of neuropsychiatric systemic lupus erythematosus. Adv Psychiatr Treat. 2009; 15:451–458.

28. Fardell JE, Vardy J, Johnston IN, Winocur G. Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther. 2011; 90:366–376.

29. Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1998; 41:41–47.

30. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006; 32:465–490.

31. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999; 42:728–734.

32. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997; 3:377–386.

33. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987; 46:605–611.

34. Inzelberg R, Bornstein NM, Reider I, Korczyn AD. The lupus anticoagulant and dementia in non-SLE patients. Dement Geriatr Cogn Disord. 1992; 3:140–145.

35. Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum. 2018; 48:240–255.

36. Adhikari T, Piatti A, Luggen M. Cognitive dysfunction in SLE: development of a screening tool. Lupus. 2011; 20:1142–1146.

37. Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2017; 44:1583–1589.

38. Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, et al. Consortium to establish a registry for Alzheimer's disease (CERAD): the first twenty years. Alzheimers Dement. 2008; 4:96–109.

39. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol. 2010; 37:2032–2038.

40. Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, Chait S, et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology. 2005; 65:1325–1327.

41. Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016; 74:41–72.

42. Petri M, Naqibuddin M, Sampedro M, Omdal R, Carson KA. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum. 2011; 41:194–202.

43. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005; 19:799–821.

44. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012; 73:993–1001.

45. Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S. Depression and systemic lupus erythematosus: a systematic review. Lupus. 2013; 22:409–416.

46. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum. 2009; 61:240–246.

47. Xie LF, Chen PL, Pan HF, Tao JH, Li XP, Zhang YJ, et al. Prevalence and correlates of suicidal ideation in SLE inpatients: Chinese experience. Rheumatol Int. 2012; 32:2707–2714.

48. Mok CC, Chan KL, Cheung EF, Yip PS. Suicidal ideation in patients with systemic lupus erythematosus: incidence and risk factors. Rheumatology (Oxford). 2013; 53:714–721.

49. Matsukawa Y, Sawada S, Hayama T, Usui H, Horie T. Suicide in patients with systemic lupus erythematosus: a clinical analysis of seven suicidal patients. Lupus. 1994; 3:31–35.

50. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfá E, Neto FL. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry. 2007; 48:14–19.

51. Huang X, Magder LS, Petri M. Predictors of incident depression in systemic lupus erythematosus. J Rheumatol. 2014; 41:1823–1833.

52. Maneeton B, Maneeton N, Louthrenoo W. Prevalence and predictors of depression in patients with systemic lupus erythematosus: a cross-sectional study. Neuropsychiatr Dis Treat. 2013; 9:799–804.

53. Nery FG, Borba EF, Viana VS, Hatch JP, Soares JC, Bonfá E, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:695–700.

54. Jarpa E, Babul M, Calderón J, González M, Martínez ME, Bravo-Zehnder M, et al. Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus. 2011; 20:58–66.

55. Sehlo MG, Bahlas SM. Perceived illness stigma is associated with depression in female patients with systemic lupus erythematosus. J Psychosom Res. 2013; 74:248–251.

56. Huang TL, Lee CT, Liu YL. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res. 2008; 42:521–525.

57. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006; 54:2505–2514.

58. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007; 36:297–315.

59. Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus. 2005; 14:571–575.

60. Figueiredo-Braga M, Cornaby C, Cortez A, Bernardes M, Terroso G, Figueiredo M, et al. Depression and anxiety in systemic lupus erythematosus: the crosstalk between immunological, clinical, and psychosocial factors. Medicine (Baltimore). 2018; 97:e11376.

61. Shakeri H, Arman F, Hossieni M, Omrani HR, Vahdani A, Shakeri J. Depression, anxiety and disease-related variables and quality of life among individuals with systemic lupus erythematosus living in Kermanshah province, Iran. Iran Red Crescent Med J. 2015; 17:e31047.

62. de Almeida Macêdo E, Appenzeller S, Lavras Costallat LT. Assessment of the Hospital Anxiety and Depression Scale (HADS) performance for the diagnosis of anxiety in patients with systemic lupus erythematosus. Rheumatol Int. 2017; 37:1999–2004.

63. Julian LJ, Gregorich SE, Tonner C, Yazdany J, Trupin L, Criswell LA, et al. Using the Center for Epidemiologic Studies Depression Scale to screen for depression in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011; 63:884–890.

64. Perry SW, Cella DF. Overdiagnosis of depression in the medically ill. Am J Psychiatry. 1987; 144:125–126.

65. Lesser RS, Walters JL, Khan R, Pebenito R, Klee S. Improvement of neuropsychiatric lupus with addition of SSRI antidepressant/antipsychotic therapy. J Clin Rheumatol. 1997; 3:294–298.

66. Kar SK, Singh A. Complex neuropsychiatric manifestations in systemic lupus erythematosus: a case study. Postępy Psychiatrii i Neurologii. 2016; 25:248–250.

67. Bhatia MS, Anurag J, Anant O. Depression in SLE responded to escitalopram. Delhi Psychiatr J. 2011; 14:383–384.

68. Li JH, Xue X, Zeng K, Zhou ZG, Huang L. Depression in systemic lupus erythematosus and its treatment. Chin J Dermatovenerol. 2010; 4:328–329.

69. Liang H, Tian X, Cao LY, Chen YY, Wang CM. Effect of psychological intervention on health-related quality of life in people with systemic lupus erythematosus: a systematic review. Int J Nurs Sci. 2014; 1:298–305.

70. Greco CM, Rudy TE, Manzi S. Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum. 2004; 51:625–634.

71. Khan S, Haddad P, Montague L, Summerton C. Systemic lupus erythematosus presenting as mania. Acta Psychiatr Scand. 2000; 101:406–408.

72. Alao AO, Chlebowski S, Chung C. Neuropsychiatric systemic lupus erythematosus presenting as bipolar I disorder with catatonic features. Psychosomatics. 2009; 50:543–547.

73. Himelhoch S, Haller E. Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid. J Clin Psychopharmacol. 1996; 16:469–470.

74. Hawro T, Krupińska-Kun M, Rabe-Jabłońska J, Sysa-Jędrzejowska A, Robak E, Bogaczewicz J, et al. Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease duration. Rheumatol Int. 2011; 31:1387–1391.

75. Yu CH, Lee MB, Tseng MM, Liao SC. Obsessive-compulsive symptoms as a manifestation of neuropsychiatric systemic lupus erythematosus. J Formos Med Assoc. 2008; 107:68–72.

76. Bai R, Liu S, Zhao Y, Cheng Y, Li S, Lai A, et al. Depressive and anxiety disorders in systemic lupus erythematosus patients without major neuropsychiatric manifestations. J Immunol Res. 2016; 2016:2829018.

77. Zhang L, Fu T, Yin R, Zhang Q, Shen B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017; 17:70.

78. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington DC: American Psychiatric Association;2013.

79. Postal M, Costallat LT, Appenzeller S. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs. 2011; 25:721–736.

80. Seguí J, Ramos-Casals M, García-Carrasco M, de Flores T, Cervera R, Valdés M, et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus. 2000; 9:584–588.

81. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007; (2):CD005594.

82. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005; 64:620–625.

83. Bortoluzzi A, Padovan M, Farina I, Galuppi E, De Leonardis F, Govoni M. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo. 2012; 64:350–359.

84. Narváez J, Ríos-Rodriguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011; 41:364–372.

85. Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008; 28:237–243.

86. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008; 47:1498–1502.

87. Denburg SD, Carbotte RM, Denburg JA. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatol. 1997; 24:998–1003.

88. Bhangle SD, Kramer N, Rosenstein ED. Corticosteroidinduced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013; 33:1923–1932.

89. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003; 61:104–107.

90. Nishimura K, Harigai M, Omori M, Sato E, Hara M. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology. 2008; 33:395–403.

91. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987; 317:265–271.

92. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006; 54:312–324.

93. Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015; 13:43.

94. Paholpak P, Rangseekajee P, Foocharoen C. Characteristics, treatments and outcome of psychosis in Thai SLE patients. J Psychosom Res. 2012; 73:448–451.

95. Pinto JP, Morais SL, Hallak JE, Dursun SM. Effectiveness of olanzapine for systemic lupus erythematosus-related psychosis. Prim Care Companion J Clin Psychiatry. 2006; 8:377–378.

96. Nayak RB, Bhogale GS, Patil NM, Chate SS. Psychosis in patients with systemic lupus erythematosus. Indian J Psychol Med. 2012; 34:90–93.

97. Muscal E, Nadeem T, Li X, Mian A, Harris TB. Evaluation and treatment of acute psychosis in children with Systemic Lupus Erythematosus (SLE): consultation-liaison service experiences at a tertiary-care pediatric institution. Psychosomatics. 2010; 51:508–514.

98. Tan LP, Tan LE. Electroconvulsive therapy for severe neuropsychiatric lupus with psychosis. J ECT. 2013; 29:243–246.

99. Chamberlin P, Kotbi N, Sanchez-Barranco P, Kragt L, Kanellopoulos D. Electroconvulsive therapy as an intervention for autoimmune neuropsychiatric disease. J ECT. 2017; 33:e44–e45.

100. Boeke A, Pullen B, Coppes L, Medina M, Cooper JJ. Catatonia associated with Systemic Lupus Erythematosus (SLE): a report of two cases and a review of the literature. Psychosomatics. 2018; 59:523–530.

101. Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry. 1985; 20:304–313.

102. Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry. 2017; 48:1–19.